SecSonar.com

Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Krystal Biotech, Inc. (KRYS) is a Biotechnology company based in US with a market capitalization of $9.1B. Revenue grew 33.9% year-over-year and the company generated $188.9M in free cash flow. This page tracks KRYS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 275 employees · IPO Sep 20, 2017

Valuation

Valuation & price

$306.29 · as of May 17, 2026 · -19.0% vs 52w high

44.8

P/E ratio

Latest-FY diluted EPS

7.44

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$375$255$135Jul 25Dec 25Jul 26Jul 7, 25$139.74Jul 9, 25$148.90Jul 11, 25$148.17Jul 15, 25$147.73Jul 17, 25$150.15Jul 21, 25$148.09Jul 23, 25$153.25Jul 25, 25$147.61Jul 29, 25$152.08Jul 31, 25$153.87Aug 4, 25$134.94Aug 6, 25$136.00Aug 11, 25$137.54Aug 13, 25$149.34Aug 15, 25$150.27Aug 19, 25$143.96Aug 21, 25$145.70Aug 25, 25$146.77Aug 27, 25$147.64Aug 29, 25$147.70Sep 3, 25$150.20Sep 5, 25$150.27Sep 9, 25$141.21Sep 11, 25$144.36Sep 16, 25$154.38Sep 18, 25$160.61Sep 22, 25$165.42Sep 24, 25$162.00Sep 26, 25$167.82Sep 30, 25$176.53Oct 2, 25$181.69Oct 6, 25$180.57Oct 8, 25$187.18Oct 10, 25$181.47Oct 14, 25$188.05Oct 16, 25$188.33Oct 21, 25$190.78Oct 23, 25$186.45Oct 27, 25$189.93Oct 29, 25$185.05Oct 31, 25$197.51Nov 4, 25$203.26Nov 6, 25$199.97Nov 10, 25$199.53Nov 12, 25$203.03Nov 14, 25$206.16Nov 18, 25$204.74Nov 20, 25$204.23Nov 25, 25$216.97Nov 28, 25$218.00Dec 2, 25$215.06Dec 4, 25$221.96Dec 8, 25$234.05Dec 10, 25$239.72Dec 12, 25$244.65Dec 16, 25$238.55Dec 18, 25$233.37Dec 22, 25$249.61Dec 24, 25$251.29Dec 29, 25$253.68Jan 2, 26$246.91Jan 6, 26$249.39Jan 8, 26$248.91Jan 12, 26$272.13Jan 14, 26$291.79Jan 16, 26$285.04Jan 21, 26$286.00Jan 23, 26$281.53Jan 27, 26$277.36Jan 29, 26$279.34Feb 2, 26$282.27Feb 4, 26$269.13Feb 9, 26$272.61Feb 11, 26$272.65Feb 13, 26$276.45Feb 18, 26$283.29Feb 20, 26$261.80Feb 24, 26$266.90Feb 26, 26$276.36Mar 2, 26$258.81Mar 4, 26$265.00Mar 6, 26$253.69Mar 10, 26$261.08Mar 12, 26$251.31Mar 17, 26$256.33Mar 19, 26$258.00Mar 23, 26$250.08Mar 25, 26$254.95Mar 27, 26$245.39Mar 31, 26$258.32Apr 2, 26$260.95Apr 7, 26$263.99Apr 9, 26$258.33Apr 13, 26$267.41Apr 15, 26$268.54Apr 17, 26$274.21Apr 22, 26$275.94Apr 24, 26$272.52Apr 28, 26$269.27Apr 30, 26$262.26May 4, 26$286.95May 6, 26$288.99May 8, 26$305.71May 12, 26$310.31May 14, 26$316.30May 18, 26$291.75May 20, 26$302.05May 22, 26$299.45May 28, 26$310.30Jun 1, 26$298.10Jun 3, 26$301.82Jun 5, 26$301.00Jun 9, 26$309.75Jun 11, 26$321.55Jun 15, 26$324.75Jun 17, 26$341.66Jun 22, 26$343.43Jun 24, 26$347.63Jun 26, 26$372.25Jul 2, 26$375.07
$134.9452-week range$378.15
Loading valuation history…

Fundamentals

Key fundamentals

$9.1B

Market cap

33.9%

Revenue growth (YoY)

92.6%

Gross margin

$188.9M

Free cash flow (USD)

-$818.5M

Net debt

Net cash position

1.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$1.0MFY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$50.7MFY 2024$290.5MFY 2025$389.1M
$0$389.1M

Free cash flow by year

2016 → 2025

FY 2016$-1.3MFY 2017$-4.1MFY 2018$-11.7MFY 2019$-25.1MFY 2020$-40.9MFY 2021$-116.3MFY 2022$-153.5MFY 2023$-100.6MFY 2024$119.2MFY 2025$188.9M
-$1.3M$188.9M

Gross margin by year

2023 → 2025

FY 202393.9%FY 202493.1%FY 202592.6%
93.9%92.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $347K · 10b5-1 PlanThomas John Charles · EVP, General Counsel · $347.3KJun 26, 2026Filing
  • Insider sellInsider Sell $7.7M · 10b5-1 PlanKrishnan Krish S · Director, President and CEO, 10% Owner · $7.7MJun 5, 2026Filing
  • Insider sellInsider Sell $7.7M · 10b5-1 PlanKrishnan Suma · Director, President, R&D, 10% Owner · $7.7MJun 5, 2026Filing
  • Insider sellInsider Sell $194K · 10b5-1 PlanThomas John Charles · EVP, General Counsel · $193.9KMay 27, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 20, 2026Filing
  • Quarterly report10-Q FiledMay 4, 2026Filing
  • 8-K eventEarnings ReleaseMay 4, 2026Filing

Questions

Frequently asked questions

What is Krystal Biotech, Inc.'s market cap?

Krystal Biotech, Inc. (KRYS) has a market capitalization of $9.1B.

What is KRYS's P/E ratio?

KRYS trades at a price-to-earnings ratio of 44.8, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is KRYS's price-to-book (P/B) ratio?

KRYS trades at 7.44 times book value per share.

Are insiders buying KRYS stock?

SEC Form 4 filings show no open-market insider buys at Krystal Biotech, Inc. in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

CYTK

Cytokinetics, Incorporated

$9.5B

TECH

Bio-Techne Corporation

$8.1B

HALO

Halozyme Therapeutics, Inc.

$8B

IBRX

ImmunityBio, Inc.

$7.9B

CORT

Corcept Therapeutics Incorporated

$7.5B

ARWR

Arrowhead Pharmaceuticals, Inc.

$10.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.